Josef Leibold

6PUBLICATIONS
67CO-AUTHORS
Molecular targetsWater treatment processesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 26, 2026
Integrated Chronic In Vivo and In Vitro Screens Uncover NFIL3 as a Driver of T-cell Dysfunction.

Nayan Jain, Yuzhe Shi, Celina May

|Jan 06, 2026
CAR-adapted PIK3CD base editing enhances T cell anti-tumor potency.

Philip Bucher, Nadine Brückner, Jule Kortendieck

|Jan 21, 2025
Immunotherapy in ovarian cancer: spatial functional genomics to unravel resistance mechanisms.

Martina Rausch, Karlotta Bartels, Josef Leibold

|Jan 04, 2024
Somatic mouse models of gastric cancer reveal genotype-specific features of metastatic disease.

Josef Leibold, Kaloyan M Tsanov, Corina Amor

|Jun 27, 2022
A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma.

Phillip M Rappold, Lynda Vuong, Josef Leibold

|Dec 22, 2018
NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.

Marcus Ruscetti, Josef Leibold, Matthew J Bott

Pageof 1